A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

This study tests a new type of CAR-T therapy called A2B395 — an "off-the-shelf" (donor-derived) engineered immune cell treatment — that is designed to target solid tumors expressing a protein called EGFR, specifically in patients whose cancer cells have lost a specific immune marker (HLA-A*02). **You may be eligible if...** - You have confirmed advanced, unresectable colorectal, lung, head/neck, breast (triple-negative), kidney, or other solid tumor cancer - Your tumor expresses EGFR and has lost HLA-A*02 (confirmed by genetic testing) - You have received required prior therapies and your cancer has progressed - You are in good physical condition (ECOG 0–1) - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have active autoimmune disease or brain metastases requiring treatment - You have had a prior allogeneic stem cell transplant or organ transplant - Your organs are not functioning well enough to tolerate CAR-T therapy Talk to your doctor to see if this trial is right for you.